Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the best oversold NASDAQ stocks to buy now. On July 1, Beam Therapeutics Inc.

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 1, ...

Beam Therapeutics Inc. (BEAM) shares ended the last trading session 5.7% higher at $21.46. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the best CRISPR stocks to buy. On June 13, Beam Therapeutics Inc.

Beam Therapeutics is also expanding its genetic disease pipeline by developing BEAM-301 and BEAM-302 for treating glycogen storage disease type 1a (GSD1a) and alpha-1 antitrypsin deficiency (AATD ...

When it comes to gene-editing companies on the cutting edge, Beam Therapeutics (BEAM 0.99%) is keen to be one of the leaders. While it's a bit of a laggard in terms of its pipeline's maturity ...

Beam Therapeutics is advancing two ex vivo base editing programs which are dubbed Beam-101 and Beam-102. As part of these studies, cells are collected from the patient.

Beam Therapeutics (NASDAQ:BEAM) is set to give its latest quarterly earnings report on Tuesday, 2024-11-05. Here's what investors need to know before the announcement.Analysts estimate that Beam ...

On Oct. 19, the early-stage gene-editing biotech Beam Therapeutics (BEAM-1.98%) announced it would be slashing its workforce by 100 employees, or around 20% of its total, while also refocusing its ...

Beam Therapeutics. Beam Therapeutics , a Cambridge-based gene editing company working to combat sickle cell disease, is aiming to start human clinical research for its experimental treatment.

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look at where Beam Therapeutics Inc. (NASDAQ:BEAM) stands against the other ...